Hollis Eden Pharmaceuticals Inc. (HEPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (122)	10/4/2001 1:48:35 PM
From: Jim Oravetz	Read Replies (1) of 138

FDA OKs Hollis-Eden Phase II Hepatitis B Drug Trial Dow Jones Newswires SAN DIEGO -- Hollis-Eden Pharmaceuticals Inc. (HEPH) received approval to begin a Phase II clinical trial of its immune regulating hormone product for the treatment of hepatitis B. In a press release Thursday, the development-stage pharmaceutical company said the clinical study will evaluate the safety, tolerance, clinical and biological effects of HE2000 in young patients infected with the hepatitis B virus at Mt. Elizabeth Medical Centre in Singapore. Company representatives weren't immediately available for further details. The company is also testing the investigational drug as a treatment for malaria in Thailand. Hollis-Eden shares recently traded at $7.25, up 22 cents or 3.1%, on Nasdaq volume of 6,900 shares. Average volume is 26,167 shares. Company Web site: holliseden.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next